GeneDx Holdings Corp reports results for the quarter ended in December - Earnings Summary

GeneDx Holdings

21/02/2024 10:42

* GeneDx Holdings Corp  WGS.OQ  reported a quarterly
adjusted loss
of 69 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-8.25.  The mean expectation of four analysts
for the quarter was for a loss of 75 cents per share. Wall
Street expected results to range from -99 cents to -60 cents per
share.
    * Revenue fell 6.4% to $57.42 million from a year ago;
analysts
expected $55.43 million. 
    * The company reported a quarterly loss of $25.77 million.
    * GeneDx Holdings Corp shares had risen by 90.5% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 5.4%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the healthcare
facilities & services peer group is also "buy"

Wall Street's median 12-month price target for GeneDx Holdings
Corp is $8.50 
This summary was machine generated from LSEG data February 21 at
10:41 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.75          -0.69          Beat
 Sep. 30 2023      -1.31          -0.82          Beat
 Jun. 30 2023      -1.31          -1.64          Missed
 Mar. 31 2023      -2.14          -2.44          Missed